Arena Pharmaceuticals

Arena initiates phase I trial of APD811 for hypertension

Friday, October 12, 2012

Arena Pharmaceuticals, a San Diego-based biopharmaceutical company focused on novel drugs for weight management, cardiovascular disease, inflammation and other disorders, has initiated dosing in a phase I multiple dose clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin (IP) receptor for the treatment of pulmonary arterial hypertension (PAH).

[Read More]

FibroGen names VP, technical development

Monday, September 12, 2011

FibroGen has named Michael Martinelli, Ph.D., vice president, technical development. In this role, Martinelli is responsible for the chemistry, manufacturing, and controls (CMC) development activities for FibroGen’s most advanced small molecule clinical candidates.

[Read More]